Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents
Barbara Rogers, CRNP, MN, AOCN®, ANP-BC
Estimated time to complete: 1 hour and 30 minutes
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Instructions for Earning CE credit
This activity has expired, credit is no longer available.